Potential Adverse Effects of Discontinuing Psychotropic Drugs: Part 2: Antidepressant Drugs
Home
Online Advanced Release
Articles for CNE credits
current issue
back issues
about the journal
contact us
advertising info
article reprints
article submission
buy a book
terms and conditions  
Careers at SLACK Inc.
 
 e-contents - sign up today
subscribe to the journal
 
find a job: NursePath.com

Glazov, What Color is Your Brain?

Psychopharmacology
Potential Adverse Effects of Discontinuing Psychotropic Drugs: Part 2: Antidepressant Drugs

Journal of Psychosocial Nursing and Mental Health Services   Vol. 48 No. 7   July 2010

By Robert H. Howland, MD

Privacy System Contact us

Share/Save/Bookmark


ABSTRACT

Understanding the particular pharmacology of different antidepressant drugs can help explain their adverse effects when they are discontinued. For all antidepressant drugs, abruptly stopping them can sometimes result in “rebound” hypomania or mania. Antidepressant drugs having anticholinergic effects often are associated with a discontinuation syndrome characterized by cholinergic rebound, with symptoms of nausea, vomiting, abdominal cramping, sweating, headache, and muscle spasms. Discontinuation of monoamine oxidase inhibitor drugs sometimes results in flu-like symptoms, dysphoria, restlessness, tachycardia, hypertension, and a delirium-like state. Serotonergic antidepressant drugs are sometimes associated with a distinct discontinuation syndrome characterized by dizziness, weakness, nausea, headache, lethargy, insomnia, anxiety, poor concentration, and paresthesias. Adverse discontinuation effects can occur with all types of antidepressant drugs, but only rarely would they be considered serious. To minimize adverse discontinuation effects and to reduce the risk of relapse or recurrence of the underlying treated condition, tapering antidepressant medication is prudent for all patients.

AUTHOR

Dr. Howland is Associate Professor of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania.

The author discloses that he has no significant financial interests in any product or class of products discussed directly or indirectly in this activity, including research support.

Address correspondence to Robert H. Howland, MD, Associate Professor of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O’Hara Street, Pittsburgh, PA 15213; e-mail: HowlandRH@upmc.edu.

Posted: June 22, 2010

doi:10.3928/02793695-20100527-98